IRB #

STUDY00019301

Title

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Principal Investigator

Jeremy Cetnar

Study Purpose

This study is being done to answer the following question:

The purpose of this study is to test the safety and tolerability of nivolumab alone and in combination with lirilumab to find out what effects, if any, it has on people.

Medical Condition(s)

CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER

Eligibility Criteria

1. Age ≥ 18 years at the time of consent
2. Confirmed urothelial cancer of the bladder
3. Eligible for cystectomy
4. Ineligible for cisplatin-based chemotherapy

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You will receive a total of 4 weeks of neoadjuvant therapy followed by radical cystectomy within 6 weeks of the completion of neoadjuvant therapy.

You will be followed for 100 days after neoadjuvant treatment for safety and then you will be followed clinically and radiographically for at least 2 years post-cystectomy or when study-wide follow-up ends per standard of care.

Minors Included

No

Contact

Clinical Trials Information Line: Phone 503-494-1080 or trials@ohsu.edu

Sponsor

PrECOG

Recruitment End

11/30/2020

Compensation Provided

No


Go Back